|
|
|
| Analysis of the Effcacy ofAnti-VEGF Drugs in the Treatment for BRVO-ME and Changes of Infammatory Factors in HumanAqueous Humor |
| Yifan Xu, Ruifeng Wang, Zheng Fu, Wenjian Tang |
| Department of Ophthalmology, the Zhengzhou Second Hospital, Zhengzhou 450000, China |
|
|
|
| Guide |
|
|
Abstract Objective: To analyze the changes of inflammatory cytokines in human aqueous humor during the medication treatment with fusion protein anti-vascular endothelial growth factor (anti-VEGF) drugs for branch retinal vein occlusion-macnlar edema (BRVO-ME). Methods: In this prospective study, Forty patients (40 eyes) with BRVO-ME who attended the Second People's Hospital of Zhengzhou from January 2018 to April 2019 were randomly selected and divided into 20 patients (20 eyes) in the Conbercepe group and 20 patients (20 eyes) in the Aflibercepe group. Three initial monthly intravitreal anti-VEGF drugs injections followed by rejection if needed was performed. The patients' best corrected visual acuity (BCVA) and centrel retinal thickness (CRT) measued by optical coherence tomography were recorded. Before each injection, a sample of the patient's aqueous humor was extracted and the indexes of VEGF, placental growth factor (PIGF), monocyte chemotactic protein-1 (MCP-1), and interleukin-6 (IL-6) were measured. In case of normally distributed data, a t-test was conducted to compare 2 groups, and χ2test was used to compare counting data. Results: After therapy, patients' BCVA and CRT signifcantly improved compared to the prior injection (P<0.05). There was no signifcant difference in the number of injections, BCVAand CRT between the two groups (P>0.05). VEGF, PIGF, and IL-6 levels in aqueous humor were signifcantly lower in both groups compared to initial levels in the following treatment (P<0.05). In the frst and second months of treatment, neither group of patients' MCP-1 factor concentration in aqueous humor substantially changed from baseline (P>0.05), however, in the third month of treatment, it decreased compared to baseline (P<0.05). There were no discernible differences between the two groups (P<0.05). Conclusions: Both conbercept and afibercept can improve the visual acuity of BRVO-ME patients, reduce macular edema, and signifcantly inhibit the angiogenic factors and infammatory factors of aqueous humor in patients with BRVO-ME. There was no signifcant difference in the clinical effcacy and inhibitory effect on aqueous humor cytokines between the two fusion protein based anti-VEGF drugs in the treatment of BRVO-ME.
|
|
Received: 05 February 2023
|
|
|
| Fund:Henan Provincial Science and Technology Department Project (222102310682) |
|
Corresponding Authors:
Ruifeng Wang, Email: wrf806@126.com
|
|
|
|
|
|
|
